Qi-Shen-Yi-Qi Dripping Pills for the Secondary Prevention of Myocardial Infarction: A Randomised Clinical Trial

Table 2

Composite endpoints of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (intention-to-be-treat analyses).

Composite endpoints	QSYQ (𝑛=1746)	Aspirin (𝑛=1759)	HR (95% CI)	𝑃 value	HR (95% CI) Adjusted for gender	𝑃 value Adjusted for gender
12-month treatment completed
Composite endpoints	52 (2.98%)	52 (2.96%)	1.02 (0.69, 1.50)	0.928	1.03 (0.70, 1.52)	0.872
Cardiovascular death	28 (1.60%)	23 (1.31%)	1.24 (0.71, 2.15)	0.450	1.26 (0.73, 2.19)	0.411
Nonfatal MI	18 (1.03%)	19 (1.08%)	0.97 (0.51, 1.84)	0.917	0.98 (0.51, 1.87)	0.952
Nonfatal stroke	6 (0.34%)	10 (0.57%)	0.61 (0.22, 1.68)	0.340	0.61 (0.22, 1.68)	0.339
6-month followup after study drugs terminated
Composite endpoints	64 (3.67%)	67 (3.81%)	0.98 (0.69, 1.38)	0.895	0.99 (0.70, 1.40)	0.957
Cardiovascular death	31 (1.78%)	30 (1.71%)	1.05 (0.64, 1.74)	0.836	1.07 (0.65, 1.77)	0.782
Nonfatal MI	26 (1.49%)	26 (1.48%)	1.03 (0.60, 1.77)	0.925	1.04 (0.60, 1.79)	0.891
Nonfatal stroke	7 (0.40%)	11 (0.63%)	0.65 (0.25, 1.68)	0.373	0.65 (0.25, 1.68)	0.377